Skip to main content
Site Search
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
News Releases
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
Normal
Get News Alerts by RSS
(opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
12/10/2021
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
12/03/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/23/2021
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
11/20/2021
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
11/19/2021
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
11/04/2021
Puma Biotechnology Reports Third Quarter 2021 Financial Results
10/21/2021
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
10/06/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/21/2021
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
09/07/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/07/2021
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08/06/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08/05/2021
Puma Biotechnology Reports Second Quarter 2021 Financial Results
07/26/2021
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
07/22/2021
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
07/02/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07/01/2021
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
06/04/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/04/2021
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
06/04/2021
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
06/04/2021
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
05/19/2021
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
05/06/2021
Puma Biotechnology Reports First Quarter 2021 Financial Results
05/04/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/22/2021
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
04/13/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/08/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/04/2021
Puma Biotechnology to Present at the Barclays Global Healthcare Conference
03/02/2021
Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
02/25/2021
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
02/25/2021
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
02/11/2021
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
02/09/2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/29/2021
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
01/19/2021
Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
01/15/2021
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
01/05/2021
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
01/04/2021
Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference